OncoCyte Corporation – Consensus Indicates Potential 53.9% Upside

Broker Ratings

OncoCyte Corporation found using ticker (OCX) have now 7 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 11 and 2 with the average target price sitting at 7.71. Given that the stocks previous close was at 5.01 this indicates there is a potential upside of 53.9%. The 50 day MA is 4.91 and the 200 moving average now moves to 3.59. The company has a market cap of $445m. Find out more information at: http://oncocyte.com

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in 2009 and is headquartered in Irvine, California.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp

AIM All Share Index